Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07777341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating the Effects of Red Grape Juice Consumption on Metabolism in Men With Coronary Artery Disease

Study acronym: GRAPEOMICS
StatusRecruiting
PhaseNot applicable
Started2026-07-10
View on ClinicalTrials.gov ↗

Amendment history

2026-08-25
minor
Study Status, Arms and Interventions, Eligibility v1
Eligibility criteria-347 characters
Inclusion Criteria: IndividualsAge agedbetween 46 toand 69 years with established. Established chronic coronary artery disease, diagnoseddefined by at least one of the following: Acute myocardial infarction occurring more than 30 days afterbefore acute myocardial infarction, angiographicenrollment; Angiographic evidence of ≥50% stenosis in one or more epicardial coronary arteries, previous; Previous percutaneous coronary intervention, or previous(PCI); Previous coronary artery bypass graft surgery, with a body mass indexgrafting (CABG). BMI) <30 kg/m². Absence and withoutof: Angina symptoms of [...] [...]
2026-08-17
minor
Original filing
Previous studies suggest that both RW and red grape juice (RGJ) have beneficial properties upon risk factors and cardiovascular events. However, the effects of grape polyphenols on metabolomics in men are still poorly understood. Recent advances in mass spectroscopy allowed substantial advances in the analysis of molecular signatures of several diseases. Therefore, the objective of this study is to evaluate the impact of RGJ on plasma metabolomics in patients with chronic coronary disease (CAD). This is a crossover, prospective, randomized and controlled study, with two 3-week interventions: 1. daily consumption of RGJ (400 mL) and 2. total abstention from foods rich in polyphenols. Plasma metabolomics will be performed by gas chromatography (GC)/mass spectroscopy (MS) by (Prof. Labate, Department of Plant Genetics, ESALQ). The sample will consist of 50 patients with chronic CAD. aged between 46 and 69 years. The inclusion and exclusion criteria were defined to achieve homogeneity of the group and avoid interference. The central hypothesis of this study is that RGJ will exert effects upon pathways involved in lipids, carbohidrates and energy production, contributing to the understanding of the mechanisms of action of polyphenols on cardiovascular health, without the risks associated with alcohol.
Trial Details
NCT Number NCT07777341
Lead Sponsor University of Sao Paulo General Hospital
Conditions Coronary Arterial Disease (CAD)
Enrollment 50 participants
Start Date 2026-07-10
Primary Completion 2028-06-10 (estimated)
Study Completion 2028-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-28